Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

<i>Background and Objectives</i>: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shinsuke Suzuki, Satoshi Toyoma, Yohei Kawasaki, Koh Koizumi, Nobuko Iikawa, Kazuhiro Shiina, Tentaro Endo, Tomoe Abe, Teppei Kouga, Takechiyo Yamada
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
head and neck squamous cell carcinoma
cetuximab
paclitaxel
immune checkpoint inhibitor
chemotherapy
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/8a00537999744e5cb5cbfd781833e46f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares